Photo from wikipedia
Sign Up to like & get
recommendations!
0
Published in 2018 at "Journal of managed care & specialty pharmacy"
DOI: 10.18553/jmcp.2018.24.9-a.s14
Abstract: This article provides an overview of the efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in the treatment of type 2 diabetes mellitus (T2DM). GLP-1 RAs stimulate pancreatic GLP-1 receptors, which increases…
read more here.
Keywords:
glp ras;
glp;
weight;
safety weekly ... See more keywords
Photo from archive.org
Sign Up to like & get
recommendations!
1
Published in 2018 at "Diabetes"
DOI: 10.2337/db18-101-or
Abstract: Background: The response to interleukin-2 (IL-2) is essential for the stability and function of regulatory T cells (Tregs) in vivo . Impaired IL-2 receptor signaling might play a crucial role in the decreased function of…
read more here.
Keywords:
low dose;
regulatory cells;
t1d patients;
novo nordisk ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2018 at "Diabetes"
DOI: 10.2337/db18-1025-p
Abstract: Diabetes therapy aims for stable glycemic control and minimal hypoglycemia risk, previously linked to day-to-day variability. In a post-hoc analysis, day-to-day fasting glycemic variability with IDegLira was compared with IGlar U100, in DUAL V (IDegLira…
read more here.
Keywords:
self novo;
novo nordisk;
variability;
day day ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2018 at "Diabetes"
DOI: 10.2337/db18-1135-p
Abstract: Semaglutide is a glucagon-like peptide (GLP-1) analog co-formulated with the absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC), to allow oral administration. The effect of oral semaglutide on the pharmacokinetics (PK) of the combined oral contraceptive…
read more here.
Keywords:
self novo;
employee self;
oral semaglutide;
novo nordisk ... See more keywords
Photo from wikipedia
Sign Up to like & get
recommendations!
0
Published in 2018 at "Diabetes"
DOI: 10.2337/db18-1182-p
Abstract: GRADE is an NIDDK-sponsored, 36-center open-label randomized trial comparing the addition of one of the four most commonly used classes of glucose-lowering medications to metformin on long-term glycemic control and patient-centered outcomes in type 2…
read more here.
Keywords:
research;
inc;
novo nordisk;
none ... See more keywords
Photo from wikipedia
Sign Up to like & get
recommendations!
0
Published in 2018 at "Diabetes"
DOI: 10.2337/db18-1822-p
Abstract: Factors associated with β-cell dysfunction in type 2 diabetes (T2D) are not well understood. We examined the association between OGTT-derived estimates of insulin sensitivity, insulin/C-peptide responses and β-cell function with baseline phenotypic characteristics in the…
read more here.
Keywords:
pharmaceuticals inc;
self;
novo nordisk;
therapeutics inc ... See more keywords
Photo from wikipedia
Sign Up to like & get
recommendations!
0
Published in 2018 at "Diabetes"
DOI: 10.2337/db18-1885-p
Abstract: Sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB) induce comparable weight loss and improvements in glycemic control despite marked differences in gastrointestinal rearrangements. We hypothesized that absorption rates of oral glucose and protein derived amino…
read more here.
Keywords:
gastric bypass;
sleeve gastrectomy;
self;
novo nordisk ... See more keywords
Photo from wikipedia
Sign Up to like & get
recommendations!
0
Published in 2018 at "Diabetes"
DOI: 10.2337/db18-1942-p
Abstract: Studies suggest that sodium-glucose cotransporter 2 inhibitors (SGLT2i) induce hyperglucagonemia, which might counteract its glucose-lowering ability in type 2 diabetes. In a randomized, placebo-controlled, double-dummy, double-blinded, cross-over study, 12 middle-aged patients with type 2 diabetes…
read more here.
Keywords:
advisory panel;
bureau self;
speaker9s bureau;
self ... See more keywords
Photo from wikipedia
Sign Up to like & get
recommendations!
1
Published in 2018 at "Diabetes"
DOI: 10.2337/db18-1956-p
Abstract: Exaggerated postprandial secretion of GLP-1 seems to contribute importantly to the metabolic effects of Roux-en-Y gastric bypass (RYGB). The surgery accelerates nutrient entry to the distal intestine, which is believed to augment GLP-1 secretion. In…
read more here.
Keywords:
gastric bypass;
self;
rygb;
novo nordisk ... See more keywords
Photo from wikipedia
Sign Up to like & get
recommendations!
1
Published in 2018 at "Diabetes"
DOI: 10.2337/db18-2-lb
Abstract: Oral semaglutide (sema), the first GLP-1 receptor agonist in a tablet formulation, is in late-stage development for the treatment of T2D. The effect and safety of oral sema (3, 7, or 14 mg once daily)…
read more here.
Keywords:
self;
support self;
research support;
novo nordisk ... See more keywords
Photo from wikipedia
Sign Up to like & get
recommendations!
1
Published in 2018 at "Diabetes"
DOI: 10.2337/db18-2012-p
Abstract: Introduction: M2a-subtype macrophage activation is known to be impaired in obesity, although the underlying mechanisms remain poorly understood. Methods: We found that the phosphorylation levels of Irs2 by IL-4 were significantly reduced along with decreased…
read more here.
Keywords:
macrophage activation;
subtype macrophage;
ltd;
novo nordisk ... See more keywords